Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch
(Thomson Reuters ONE) -
October 14, 2014
TORONTO, CANADA - Cynapsus Therapeutics Inc. (CTH: TSX-V) (OTCQX: CYNAF) today
announced that its APL-130277 for Parkinson's was recognized as one of the Top
Ten Neurology Projects to Watch by a joint selection committee including Dr.
Harry Tracy, a noted authority on pharmacological interventions for diseases of
the brain. Dr. Tracy is also the editor of the respected biotechnology
publication NeuroPerspective, which is utilized by pharmaceutical companies and
investors around the world. Cynapsus has been invited to present the APL-130277
project at the Therapeutic Area Partnerships Meeting taking place on November
19 to 21, 2014, at the Hyatt Regency Boston.
Criteria for selection of the Top 10 Neurology Projects to Watch are:
· Large market, large unmet need, with increasing opportunity
· History of the molecule and drug
· Strong science
· Strong company
· Diversity of indications
· Potential for new opportunities beyond the initial indications
· Multi-level partnering opportunities, i.e., biotech to biotech as
well as pharma to biotech
Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. OFF episodes are a
complication of Parkinson's disease that leave patients rigid and unable to move
and communicate. Approximately 25% to 50% of Parkinson's patients experience
OFF episodes, which can occur 1 to 6 times daily and last between 30 and 120
minutes.
Today, apomorphine is the only drug that can rapidly convert a patient from OFF
(unable to move) to ON (fully functional). Unfortunately for Parkinson's
patients, apomorphine is primarily only available as a needle injection, which
can be painful and difficult to administer.
Cynapsus' APL-130277 drug candidate is the only oral formulation of apomorphine
for the treatment of OFF episodes. APL-130277 is a thin film strip that a
Parkinson's patient can place under their tongue when an OFF episode is
starting. If approved, APL-130277 will provide patients with a convenient and
more tolerable alternative to multiple daily injections. As a new means of
delivering an approved drug, this clinical stage project is expected to follow a
505(b)(2) regulatory and clinical path which is expected to culminate in a New
Drug Approval application in 2016.
"We are honored to be recognized from among the hundreds of worthy neuroscience
projects, worldwide. This nomination provides further independent validation of
the potential of APL-130277, and comes only a few months after receiving a
second grant from The Michael J. Fox Foundation for Parkinson's Research. We
are now focused on completing efficacy and safety studies in Parkinson's
patients over the next 12 to 18 months," said Mr. Anthony Giovinazzo, President
and Chief Executive Officer of Cynapsus.
About Therapeutics Area Partnerships
The 8th Annual Therapeutic Area Partnerships is one of the industry's most
targeted and efficient partnering meeting for life science companies seeking
partnerships in the top therapeutic areas: Neuroscience, Oncology,
Cardiovascular/Metabolic, Infectious, Inflammatory Diseases and other hot
therapeutic areas. Decision-makers focusing on these therapeutic categories can
meet to develop strategic alliances in a personal and interactive setting that
combines company presentations, 1:1 meetings and networking functions. More
information is available at
http://www.iirusa.com/therapeuticareapartnership/home.xml.
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of OFF motor
symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an
easy-to-administer, fast-acting reformulation of apomorphine, which is the only
approved drug (in the United States, Europe, Japan and other countries) to
rescue patients from OFF episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
(NDA) expected to be submitted in 2016.
Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on a recent
study and the results of the Corporation's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients experience OFF
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses.
More information about Cynapsus (TSX-V: CTH) (OTCQX: CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.
Contact Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg(at)cynapsus.ca
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams(at)cynapsus.ca
Forward Looking Statements
This announcement contains "forward-looking statements" within the meaning of
applicable securities laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements, including
but not limited to those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its March 26, 2014, Annual
Information Form and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although Cynapsus has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements, there may
be other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place undue
reliance on forward-looking statements. Cynapsus does not undertake to update
any forward-looking statements, except in accordance with applicable securities
laws.
Neither the TSX Venture Exchange nor the OTCQX International has approved or
disapproved of the contents of this press release.
-30-
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cynapsus Therapeutics Inc. via GlobeNewswire
[HUG#1862360]
Unternehmensinformation / Kurzprofil:
Datum: 14.10.2014 - 07:00 Uhr
Sprache: Deutsch
News-ID 343588
Anzahl Zeichen: 8869
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch"
steht unter der journalistisch-redaktionellen Verantwortung von
Cynapsus Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
